Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and PK of HR20033 (Henagliflozin/Metformin) in Healthy Chinese Subjects
NCT05120219Phase 1Unknown
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 8, Area Under the Curve from time 0 to last measurable concentration at Day 8 and 3 more. Status: unknown.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05120219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120219.